Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome

OBJECTIVE: To evaluate the safety and preliminary pharmacokinetics of a pharmaceutical formulation of purified cannabidiol (CBD) in children with Dravet syndrome. METHODS: Patients aged 4–10 years were randomized 4:1 to CBD (5, 10, or 20 mg/kg/d) or placebo taken twice daily. The double-blind trial...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neurology
Autors principals: Devinsky, Orrin, Patel, Anup D., Thiele, Elizabeth A., Wong, Matthew H., Appleton, Richard, Harden, Cynthia L., Greenwood, Sam, Morrison, Gilmour, Sommerville, Kenneth
Format: Artigo
Idioma:Inglês
Publicat: Lippincott Williams & Wilkins 2018
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5890607/
https://ncbi.nlm.nih.gov/pubmed/29540584
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/WNL.0000000000005254
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars